AIM ImmunoTech (AIM) Research & Development (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Research & Development came in at $482000.0 in Q1 2026, down 55.37% YoY from $1.1 million in Q1 2025, and down 54.66% on a QoQ basis from $1.1 million in Q4 2025.
AIM ImmunoTech (AIM) Research & Development (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Research & Development data on file, last reported at $482000.0 in Q1 2026.
- Quarterly Research & Development fell 55.37% year-over-year to $482000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 37.55% YoY) and the FY2025 annual result came in at $3.9 million, down 36.68% from the prior year.
- Research & Development retreated to $482000.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.4 million in Q3 2022 to a low of $200000.0 in Q4 2022.
- A 5-year average of $1.9 million and a median of $1.4 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development slumped 91.45% — and 2023, when it jumped 1500.0%.
- Tracing AIM's Research & Development over 5 years: stood at $200000.0 in 2022, then jumped by 1500.0% to $3.2 million in 2023, then sank by 48.0% to $1.7 million in 2024, then tumbled by 36.12% to $1.1 million in 2025, then slumped by 54.66% to $482000.0 in 2026.
- The last three Research & Development figures came in at $482000.0 (Q1 2026), $1.1 million (Q4 2025), and $607000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 589,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 589,000.00 |
| Mar 31, 2026 | 482,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 607,000.00 |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 2.73 Mn |
| Jun 30, 2023 | 2.95 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | 6.40 Mn |
| Jun 30, 2022 | 2.48 Mn |
| Mar 31, 2022 | 1.04 Mn |
| Dec 31, 2021 | 2.34 Mn |
| Sep 30, 2021 | 2.01 Mn |